Cue Biopharma, Inc. Payments to Acquire Debt Securities, Available-for-sale
Cue Biopharma, Inc. (CUE) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2022-03-16
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-12-31 was -$133.00.
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-09-30 was $0.00.
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-06-30 was -$1.00K.
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-03-31 was $9.95M.
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $9.95M, a 34.26% decline from fiscal 2019.
- Cue Biopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2019 was $15.13M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-16 | |||
| 2020-12-31 | -$133.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$133.00 derived: sum of 2 quarters · filed 2022-03-16 | -$1.13K derived: sum of 3 quarters · filed 2022-03-16 | $9.95M 10-K · filed 2022-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$1.00K derived: sum of 2 quarters · filed 2021-11-09 | $9.95M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $9.95M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $9.95M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $15.13M 10-K · filed 2021-03-09 | |||
| 2018-09-30 | $23.31M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |